Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy

Saigusa,Susumu; Inoue,Yasuhiro; Tanaka,Koji; Okugawa,Yoshinaga; Toiyama,Yuji; Uchida,Keiichi; Mohri,Yasuhiko; Kusunoki,Masato

doi:10.3892/mco.2013.189

Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy

Authors:
- Susumu Saigusa
- Yasuhiro Inoue
- Koji Tanaka
- Yoshinaga Okugawa
- Yuji Toiyama
- Keiichi Uchida
- Yasuhiko Mohri
- Masato Kusunoki
View Affiliations

Affiliations: Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan
Published online on: September 20, 2013 https://doi.org/10.3892/mco.2013.189
Pages: 99-104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Preoperative chemoradiotherapy (CRT) is an effective tool for local control that functions by inducing cancer cell apoptosis and inhibiting cell growth. The aim of this study was to evaluate the expression of caspase‑cleaved keratin 18 cytoskeletal protein, M30, which is known as an apoptotic marker in residual rectal cancer following preoperative CRT. A total of 72 patients with rectal cancer who had undergone preoperative CRT were enrolled in this study. Immunostaining with M30 cytodeath antibody was performed and the correlation between M30 staining and clinicopathological variables was analyzed. Furthermore, we examined the correlation of M30 staining with the expression of Bax, Bcl‑2, Ki67 and PCNA using transcriptional and immunohistochemical analyses. The results showed that 34 (47%) patients were positive for M30 staining. Lack of M30 expression was significantly correlated with advanced T stage, postoperative stage and tumor recurrence (P<0.05). Patients with M30 staining had better recurrence‑free survival (RFS) than those without it (P=0.0301). In the immunohistochemical analysis, residual cancer cells with M30 staining lacked Ki67 expression. No significant correlation was observed between M30 positivity and the gene expression of apoptotic and proliferative markers. In conclusion, findings of the present study suggested that the evaluation of M30 expression may be useful in the prediction of tumor recurrence in rectal cancer patients who have been treated with preoperative CRT.

View Figures

View References

1.	Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
2.	van den Brink M, Stiggelbout AM, van den Hout WB, et al: Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol. 22:3958–3964. 2004.PubMed/NCBI
3.	Guillem JG, Chessin DB, Cohen AM, et al: Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 241:829–838. 2005. View Article : Google Scholar
4.	Smith FM, Reynolds JV, Miller N, et al: Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol. 32:55–64. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Bertolini F, Bengala C, Losi L, et al: Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 68:1455–1461. 2007. View Article : Google Scholar
6.	Rodel C, Martus P, Papadoupolos T, et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 23:8688–8696. 2005. View Article : Google Scholar : PubMed/NCBI
7.	Bujko K, Michalski W, Kepka L, et al: Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys. 67:369–377. 2007. View Article : Google Scholar
8.	Dhadda AS, Dickinson P, Zaitoun AM, et al: Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer. Eur J Cancer. 47:1138–1145. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Topova L, Hellmich G, Puffer E, et al: Prognostic value of tumor response to neoadjuvant therapy in rectal carcinoma. Dis Colon Rectum. 54:401–411. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Tannapfel A, Nusslein S, Fietkau R, et al: Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 41:585–591. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Rupa JD, de Bruine AP, Gerbers AJ, et al: Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct clinical outcome. Cancer. 97:2404–2411. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Leers MP, Kolgen W, Bjorklund V, et al: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 187:567–572. 1999. View Article : Google Scholar : PubMed/NCBI
13.	Caulin C, Salvesen GS and Oshima RG: Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol. 138:1379–1394. 1997. View Article : Google Scholar : PubMed/NCBI
14.	de Bruin EC, van de Velde CJ, van de Pas S, et al: Prognostic value of apoptosis in rectal cancer patients of the Dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res. 12:6432–6436. 2006.PubMed/NCBI
15.	de Heer P, Gosens MJ, de Bruin EC, et al: Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. Clin Cancer Res. 13:2955–2960. 2007.PubMed/NCBI
16.	Gosens MJ, Dresen RC, Rutten HJ, et al: Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours. Ann Oncol. 19:2026–2032. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Yoshikawa R, Kusunoki M, Yanagi H, et al: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 61:1029–1037. 2001.
18.	Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 358:1291–1304. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Ryan R, Gibbons D, Hyland JM, et al: Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 47:141–146. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Saigusa S, Tanaka K, Toiyama Y, et al: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 16:3488–3498. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Adell GC, Zhang H, Evertsson S, et al: Apoptosis in rectal carcinoma: prognosis and recurrence after preoperative radiotherapy. Cancer. 91:1870–1875. 2001. View Article : Google Scholar : PubMed/NCBI
22.	Koornstra JJ, Rijcken FE, De Jong S, et al: Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology. 44:9–17. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Reed JC: Double identity for proteins of the Bcl-2 family. Nature. 387:773–776. 1997. View Article : Google Scholar : PubMed/NCBI